New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:31 EDTAMRN, KERXKeryx slide attributable to Zerenex market exclusivity worries, The Street says
The 22% decline in Keryx Pharmaceuticals (KERX) seen on Friday was attributable to concerns raised by a report from IPD Analytics about the company's ability to gain FDA "New Chemical Entity" status for Zerenex, according to The Street's Adam Feuerstein. The author notes that Amarin (AMRN) shares are sometimes volatile over a similar concern, namely that a key drug may not be able to secure NCE status, which grants five years of market exclusivity for a unique pharmaceutical compound. Reference Link
News For KERX;AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
08:48 EDTKERXKeryx management to meet with JMP SEcurities
Subscribe for More Information
March 23, 2015
13:43 EDTKERXKeryx mentioned cautiously in a Seeking Alpha Pro article
Subscribe for More Information
March 20, 2015
07:55 EDTKERXKeryx survey results positive, says Oppenheimer
After surveying 50 nephrologists/nurses/dietitians at U.S. dialysis clinics, Oppenheimer reported that dialysis providers it surveyed expect to prescribe Keryx's Auryxia in 11% of new starts and about 12% of switchers . As a result of this data points and other data from the survey, the firm expects Auryxia prescription trends to improve. It keeps an $18 price target and Outperform rating on the shares.
05:51 EDTAMRNStocks with implied volatility movement; AMRN EWG
Stocks with implied volatility movement; Amarin (AMRN) 140, iShares MSCI Germany (EWG) 20 according to iVolatility.
March 17, 2015
08:54 EDTAMRNAmarin says study suggest EPA pretreatment reduces oxidative damage
Subscribe for More Information
March 16, 2015
10:07 EDTAMRNHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use